NEW YORK, August 21, 2017 /PRNewswire/ --
If you want a Stock Review on PTHN, ZTS, IRWD, or MDCO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. The Generic Drugs market can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, this market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. For today, DailyStockTracker.com scans the performances of Patheon N.V. (NYSE: PTHN), Zoetis Inc. (NYSE: ZTS), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), and The Medicines Co. (NASDAQ: MDCO). These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at:
Amsterdam, the Netherlands-based Patheon N.V.'s shares rose 0.06%, finishing last Friday's session at $34.97. A total volume of 67,799 shares was traded. Over the last month and the previous three months, the stock has advanced 0.11% and 1.04%, respectively. Furthermore, the Company's shares have gained 21.80% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 0.24% and 15.44%, respectively. Additionally, shares of Patheon, which provides outsourced pharmaceutical development and manufacturing services, have a Relative Strength Index (RSI) of 55.35. Your complete research report on PTHN can be retrieved for free at:
On Friday, shares in Parsippany, New Jersey headquartered Zoetis Inc. ended the session 0.25% lower at $60.75. The stock recorded a trading volume of 1.51 million shares. The Company's shares have gained 0.73% in the previous three months and 13.49% on an YTD basis. The stock is trading above its 200-day moving average by 7.97%. Moreover, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have an RSI of 43.87.
On August 03rd, 2017, Zoetis announced the appointment of Dr. Linda Rhodes, an accomplished scientist, academic, veterinarian, and business leader in animal health, to its Board of Directors, effective at the close of business that day. Dr. Rhodes will serve on the Quality and Innovation Committee of the Board. She most recently served as the Chief Scientific Officer of Aratana Therapeutics, a publicly traded animal health company, from 2012 to 2016.
On August 07th, 2017, research firm Goldman resumed its 'Neutral' rating on the Company's stock, with a target price of $62 per share. A free report on ZTS is just a click away at:
Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc.'s stock closed the day flat at $14.50. A total volume of 1.29 million shares was traded, which was above their three months average volume of 1.19 million shares. The Company's shares are trading 12.71% below their 200-day moving average. Additionally, shares of Ironwood Pharma, which engages in the research, development, and commercialization of human therapeutic products, have an RSI of 25.18.
On July 21st, 2017, research firm JP Morgan downgraded the Company's stock rating from 'Overweight' to 'Neutral'.
On August 03rd, 2017, Ironwood Pharma provided an update on its Q2 2017 results. For Q2 2017, total revenues were $65.1 million; operating expenses were $106.1 million; net interest expense was $8.6 million; GAAP net loss was $44.2 million; and non-GAAP net loss was $42.2 million. The Company ended the quarter with $272.9 million of cash, cash equivalents, and available-for-sale securities. Sign up for your complimentary research report on IRWD at:
Shares in Parsippany, New Jersey-based The Medicines Co. recorded a trading volume of 775,467 shares. The stock ended at $35.50, rising 0.28% from the last trading session. The Company's shares have gained 4.60% on an YTD basis. The stock is trading below its 50-day moving average by 6.45%. Furthermore, shares of Medicines Co., which provides medicines for patients in acute and intensive care hospitals worldwide, have an RSI of 39.65.
On August 09th, 2017, Medicines Co. reported its financial results for Q2 and six months ended June 30th, 2017. For Q2 2017, worldwide net revenue was $18.7 million, and GAAP net loss from continuing operations was $397.3 million. For H1 2017, worldwide net revenue was $43.0 million, and GAAP net loss from continuing operations was $499.9 million. Register for free on DailyStockTracker.com and download the latest research report on MDCO at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA